Can Rite Aid Save Itself With This Restructuring?

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Can Rite Aid Save Itself With This Restructuring?

© Thinkstock

Rite Aid Corp. (NYSE: RAD) announced on Wednesday morning that there will be some changes in its executive leadership as well as some restructuring. At this point, investors are welcoming anything to pull this stock out of the tailspin it has experienced over the past two years.

Excluding Wednesday’s move, Rite Aid had underperformed the broad markets, with its stock down about 4% year to date. However, the charts get worse over the past 52 weeks, with the stock down about 61%. As far back as January 2017, this was an $8 stock.

As part of the leadership transition, John Standley will step down as chief executive officer. The board of directors will promptly commence a search process for a new CEO, and Standley will remain in the position until the appointment of his successor.

[nativounit]

Rite Aid also announced additional management changes, each of which is effective immediately:

  • Bryan Everett, chief operating officer of Rite Aid Stores has been promoted to chief operating officer of the company, succeeding Kermit Crawford who is leaving the company.
  • Matt Schroeder, chief accounting officer and treasurer, has been promoted to chief financial officer. Schroeder is succeeding Darren Karst who is leaving the company this spring after supporting a brief transition.
  • Brian Hoover, group vice president and controller, has been promoted to chief accounting officer.
  • Jocelyn Konrad, executive vice president, pharmacy, has been promoted to executive vice president, pharmacy and retail operations.
  • Derek Griffith, executive vice president, store operations is leaving the company.

Separately, Rite Aid announced actions that will reduce managerial layers and consolidate roles across the organization, resulting in the elimination of roughly 400 full-time positions, or more than 20% of the corporate positions located at headquarters and across the field organization. Roughly, two-thirds of the reductions will take place immediately, with the balance by the end of fiscal 2020.

Shares of Rite Aid closed Tuesday at $0.68, in a 52-week range of $0.60 to $2.12. The consensus price target is $0.75. Following the announcement, the stock was up about 10% at $0.74 in early trading indications Wednesday.

[recirclink id=534043]

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618